European regulators recommended approval of Novartis's multiple sclerosis pill Gilenya on Friday, consolidating its lead as the first pill to treat the disease.
The green light from the European Medicines Agency in London follows approval in the United States last month, where it has gone on sale at an average cost of $48,000 per patient a year.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309